Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114
Debt
Debt-to-Equity Ratio0.12
Current Ratio26.02
Quick Ratio26.02
Price-To-Earnings
Trailing P/E Ratio-4.67
Forward P/E Ratio-8.60
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book5.78
Profitability
EPS (Most Recent Fiscal Year)($3.67)
Net Income$-51,000,000.00
Net MarginsN/A
Return on Equity-83.10%
Return on Assets-53.69%
Miscellaneous
Employees39
Outstanding Shares56,180,000
Market Cap$1.04 billion
Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions
What is Apellis Pharmaceuticals' stock symbol?
Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How were Apellis Pharmaceuticals' earnings last quarter?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its earnings results on Tuesday, July, 31st. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.14. View Apellis Pharmaceuticals' Earnings History.
When is Apellis Pharmaceuticals' next earnings date?
What price target have analysts set for APLS?
6 brokers have issued twelve-month target prices for Apellis Pharmaceuticals' shares. Their forecasts range from $23.00 to $53.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $35.60 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.
What is the consensus analysts' recommendation for Apellis Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.
What are Wall Street analysts saying about Apellis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (8/3/2018)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month price target of $52/share on the company’s R&D day hosted on 6/26. Apellis reviewed details for its two Phase 3 programs with APL-2 in geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), presented initial results from its Phase 2 study in autoimmune hemolytic anemia (AIHA), and provided an update on its Phase 2 PNH study. The company also reported early enrollment of the first patient for the Phase 3 PNH trial. Based on the totality of clinical data supporting APL-2 in GA and PNH, we believe the drug is well-positioned to succeed for both indications, which appear to have blockbuster potential." (6/27/2018)
Who are some of Apellis Pharmaceuticals' key competitors?
Some companies that are related to Apellis Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD) and The Medicines (MDCO).
Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the folowing people:
- Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Pascal Deschatelets, Co-Founder & COO (Age 48)
- Mr. Timothy E. Sullivan, CFO & Treasurer (Age 47)
- Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
- Mr. David O. Watson, Gen. Counsel & VP of Corp. Devel. (Age 45)
When did Apellis Pharmaceuticals IPO?
(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.
Has Apellis Pharmaceuticals been receiving favorable news coverage?
Media headlines about APLS stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a media and rumor sentiment score of 0.23 on Accern's scale. They also assigned news articles about the company an impact score of 47.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Apellis Pharmaceuticals.
Who are Apellis Pharmaceuticals' major shareholders?
Apellis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hillhouse Capital Management Ltd. (7.70%), venBio Partners L.P. (5.86%), BlackRock Inc. (4.98%), FMR LLC (2.39%), Victory Capital Management Inc. (1.67%) and Millennium Management LLC (1.59%). Company insiders that own Apellis Pharmaceuticals stock include Global Strategic Fund I Venbio and Lukas Scheibler. View Institutional Ownership Trends for Apellis Pharmaceuticals.
Which major investors are buying Apellis Pharmaceuticals stock?
APLS stock was bought by a variety of institutional investors in the last quarter, including venBio Partners L.P., Hillhouse Capital Management Ltd., BlackRock Inc., Millennium Management LLC, Victory Capital Management Inc., FMR LLC, Opaleye Management Inc. and Baker BROS. Advisors LP. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio and Lukas Scheibler. View Insider Buying and Selling for Apellis Pharmaceuticals.
How do I buy shares of Apellis Pharmaceuticals?
Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apellis Pharmaceuticals' stock price today?
One share of APLS stock can currently be purchased for approximately $17.12.
How big of a company is Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a market capitalization of $1.04 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.
How can I contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]
MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
